Antonio Abbate, MD & Ben Van Tassell, PharmD work at Virginia Commonwealth University. In this video Dr. Abbate and Dr. Van Tassell speak on the Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) (VCU-ART3) trial. https://clinicaltrials.gov/ct2/show/NCT01950299?recrs=e&cond=Heart&phase=23&lupd_s=01%2F01%2F2019&lupd_e=01%2F03%2F2022&draw=3&rank=590Abstract-VCU-ART3 is a randomized double-blind clinical trial in patients with ST-segment elevation myocardial infarction (STEMI) that compares the impact of anakinra high dosage vs. anakinra standard dose vs. placebo on the acute rise and fall of plasma C reactive protein levels over the first 14 days.Description in detail:VCU-ART3 is a randomized double-blind clinical trial in patients with ST-segment elevation myocardial infarction (STEMI) that compares the impact of anakinra high dosage vs. anakinra standard dose vs. placebo on the acute rise and fall of plasma C reactive protein levels over the first 14 days. - Myocardial Infarction - 634_600c9efaa3c99

Antonio Abbate, MD & Ben Van Tassell, PharmD - Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) (VCU-ART3) @AbbateAntonio   @bvantassell  #VCUART3Trial #MyocardialI...

Antonio Abbate, MD & Ben Van Tassell, PharmD - Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) (VCU-ART3) @AbbateAntonio @bvantassell #VCUART3Trial #MyocardialI...

8 months
220 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Antonio Abbate, MD & Ben Van Tassell, PharmD work at Virginia Commonwealth University. In this video Dr. Abbate and Dr. Van Tassell speak on the Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) (VCU-ART3) trial.

https://clinicaltrials.gov/ct2/show/NCT01950299?recrs=e&cond=Heart&phase=23&lupd_s=01%2F01%2F2019&lupd_e=01%2F03%2F2022&draw=3&rank=590


Abstract-
VCU-ART3 is a randomized double-blind clinical trial in patients with ST-segment elevation myocardial infarction (STEMI) that compares the impact of anakinra high dosage vs. anakinra standard dose vs. placebo on the acute rise and fall of plasma C reactive protein levels over the first 14 days.

Description in detail:

VCU-ART3 is a randomized double-blind clinical trial in patients with ST-segment elevation myocardial infarction (STEMI) that compares the impact of anakinra high dosage vs. anakinra standard dose vs. placebo on the acute rise and fall of plasma C reactive protein levels over the first 14 days.

Up Next Autoplay